Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Oklahoma Cardiovascular Research Group
mi
from
Oklahoma City, OK
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
Oklahoma Cardiovascular Research Group
mi
from
Oklahoma City, OK
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Status: Archived
BWH/FH/DCI Outpatient Dialysis Unit
mi
from
Boston, MA
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Status: Archived
Updated: 1/1/1970
BWH/FH/DCI Outpatient Dialysis Unit
mi
from
Boston, MA
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Status: Archived
Veterans Affairs Medical Center - Hines
mi
from
Hines, IL
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Hines
mi
from
Hines, IL
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Archived
Northwestern University
mi
from
Chicago, IL
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01339 Boehringer Ingelheim Investigational Site
mi
from
Lomita, CA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10009 Boehringer Ingelheim Investigational Site
mi
from
West Palm Beach, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10009 Boehringer Ingelheim Investigational Site
mi
from
West Palm Beach, FL
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.61.01038 Boehringer Ingelheim Investigational Site
mi
from
Honolulu, HI
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.61.01038 Boehringer Ingelheim Investigational Site
mi
from
Honolulu, HI
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10010 Boehringer Ingelheim Investigational Site
mi
from
Billerica, MA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10010 Boehringer Ingelheim Investigational Site
mi
from
Billerica, MA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01014 Boehringer Ingelheim Investigational Site
mi
from
Chesterfield, MO
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01014 Boehringer Ingelheim Investigational Site
mi
from
Chesterfield, MO
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01142 Boehringer Ingelheim Investigational Site
mi
from
Endwell, NY
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01142 Boehringer Ingelheim Investigational Site
mi
from
Endwell, NY
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.25.10010 Boehringer Ingelheim Investigational Site
mi
from
Greenville, NC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.25.10010 Boehringer Ingelheim Investigational Site
mi
from
Greenville, NC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10005 Boehringer Ingelheim Investigational Site
mi
from
Bethlehem, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10005 Boehringer Ingelheim Investigational Site
mi
from
Bethlehem, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1200.32.2609 Boehringer Ingelheim Investigational Site
mi
from
Corpus Christi, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Efficacy and Safety of BI 10773 in Patients With Type 2 Diabetes and Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Fluid Balance and Clinical Outcomes
Investigation of the Effect of Post-operative Fluid Balance on Inflammatory Mediators in Patients Undergoing Cardiovascular Surgery
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Fluid Balance and Clinical Outcomes
Investigation of the Effect of Post-operative Fluid Balance on Inflammatory Mediators in Patients Undergoing Cardiovascular Surgery
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: A Pilot Study
Status: Archived
University of Louisville Hospital
mi
from
Louisville, KY
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: A Pilot Study
Status: Archived
Updated: 1/1/1970
University of Louisville Hospital
mi
from
Louisville, KY
Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant
Status: Archived
North America
mi
from
New York, NY
Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant
Status: Archived
Updated: 1/1/1970
North America
mi
from
New York, NY
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO